And for an inventory of of all stocks sorted by upside potential based on analyst target worth, see our Top Price Target page. We observe news headlines from hundreds of stories shops and tag them by company. This chart compares the number of articles about this company in the final seven days in contrast with the common variety of articles about this firm on a typical week. © 2022 Market knowledge offered is at least 10-minutes delayed and hosted by Barchart Solutions.
This makes Pulmatrix the world’s 5966th most dear company by market cap based on our information. The market capitalization, commonly known as market cap, is the whole market value 43 courthouse dr guildhall vt of a publicly traded company’s excellent shares and is often used to mesure how much a company is price. 1 brokerages have issued 12-month price targets for Pulmatrix’s stock.
We have 9 totally different rankings for each stock that will assist you appreciate its future potential. Information is offered ‘as-is’ and solely for informational purposes and is not advice. WallStreetZen doesn’t bear any accountability for any losses or injury that will occur on account of reliance on this information.
Receive a free world-class investing training from MarketBeat. Learn about monetary phrases, types of investments, trading strategies and extra. One share of PULM stock can currently be bought for roughly $5.sixty seven. Pulmatrix has solely been the subject of 1 analysis reports in the past 90 days. According to analysts’ consensus worth target of $10.00, Pulmatrix has a forecasted upside of 76.4% from its present price of $5.sixty seven.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to forestall and deal with respiratory and different illnesses with unmet medical wants in the United States. The firm focuses on developing merchandise primarily based on its inhaled Small Particles Easily Respirable and Emitted know-how, which permits supply of small or massive molecule drugs to the lungs by inhalation for native or systemic applications. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix, Inc., a medical stage biotechnology company, discovers and develops inhaled therapies to stop and treat respiratory and other diseases with unmet medical needs within the United States. The company focuses on developing products primarily based on its inhaled small particles easily respirable and emitted technology, which permits supply of small or massive molecule medicine to the lungs by inhalation for native or systemic applications. Pulmatrix, Inc., a medical stage biopharmaceutical firm, engages in creating inhaled therapies to deal with critical pulmonary ailments utilizing its iSPERSE expertise.
View which shares have been most impacted by COVID-19. The company’s common rating rating is 3.00, and is predicated on 1 buy ranking, no maintain rankings, and no promote ratings. For more perception on analysts targets of PULM, see our PULM worth goal page.